Moshkevich Solomon sold $905K of NTRA

Moshkevich Solomon (PRESIDENT, CLINICALDIAGNOSTICS) sold 2,172 shares of Natera, Inc. (NTRA) at an average of $416.88 ($406.00–$426.34, $0.91M total) across 2 trades over 2026-10-27 to 2026-10-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Moshkevich Solomon
Published Oct 30, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 2:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The filing provides fresh, primary‑source data on insider activity, offering modest insight into potential short‑term price pressure.

02

Market read

Primary insider sale filing; modest relevance for traders monitoring Natera's stock.

03

What to watch

The insider retains a large stake (over 100k shares) and the sale size is small relative to overall float.

Relevance 4/10Novelty 6/10Timing: post-market

Background

SEC Form 4 filing discloses an insider transaction by Natera's President of Clinical Diagnostics.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

President of Natera sold 2,172 shares for $905,467 via a 10b5-1 plan, reducing holdings to 104,742 shares.

Expected impact

likely slight downward pressure as investors price in the insider sell.

Evidence & confidence

C‑level insider sales, even pre‑arranged, are often viewed as a negative signal, but the amount ($0.9M) is modest relative to the company's market cap.

Market effects

None

None

Low

Counterpoint

The sale could be purely procedural under the 10b5-1 plan and not reflect negative sentiment.

Key entities

  • Natera, Inc.

    US‑listed genetic testing company (NASDAQ: NTRA).

  • Moshkevich Solomon

    President, Clinical Diagnostics at Natera, reporting the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.